Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TSMA-based SLP vaccine |
Synonyms | |
Therapy Description |
TSMA-based SLP vaccine is a personalized synthetic long peptide (20-35 amino acid) vaccine derived from multiple patient-specific tumor-specific mutant antigens (TSMA), which may induce cytotoxic immune response against tumor cells expressing TSMAs (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TSMA-based SLP vaccine | Personalized Synthetic Long Peptide Vaccine|Personalized SLP Vaccine | TSMA-based SLP vaccine is a personalized synthetic long peptide (20-35 amino acid) vaccine derived from multiple patient-specific tumor-specific mutant antigens (TSMA), which may induce cytotoxic immune response against tumor cells expressing TSMAs (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|